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ABSTRACT
THE DEFORMABILITY OF RED BLOOD CELLS IN MYALGIC
ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS)
by Brendan Schmidt
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disease that
causes profound fatigue in its sufferers as well as loss of concentration, headaches, and
sleep abnormalities. Unfortunately, the disease is poorly diagnosed, and etiology is not
known. Although the ME/CFS patients do not show anemic readings, and their arterial
partial pressure is normal, it is possible that their extreme post-exertional malaise stems
from poor microvascular perfusion and oxygenation. Previous studies have indicated that
the red blood cells (RBCs) in ME/CFS patients show evidence of oxidative damage. We
hypothesized that the RBC deformability metrics can serve as a reliable biomarker of
ME/CFS diagnosis. A corollary to this hypothesis in that the loss of RBC function could
result in tissue oxygenation and microvascular perfusion being impaired which could
manifest in ME/CFS’s symptoms. To test this hypothesis, RBCs were fed through a
custom microfluidic device from both healthy control and ME/CFS patients while a highspeed camera recorded the movement of RBCs through the channels. Using imaging
software, different deformability metrics were measured including the velocity of the
RBC through the device and changes in the shape of the RBC. We found the stiffness of
the RBCs in ME/CFS patients was modestly, but significantly increased compared to
those of the RBCs from healthy controls. These conclusions suggest that RBC
deformability may serve as a biomarker for ME/CFS and that the impaired RBC transport
through capillaries/microvessels could explain some of the ME/CFS symptoms.
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CHAPTER ONE: INTRODUCTION
1.1 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Chronic Fatigue Syndrome (ME/CFS) is a disease that causes profound fatigue in
patients that cannot be alleviated by rest. There are many symptoms that manifest
themselves in ME/CFS patients including loss of memory and concentration, headaches,
or extreme tiredness after any type of physical exertion. [1] Unfortunately, while the
disease can be characterized by the above symptoms, very little is known about the
mechanism of the disease since it does not attack a specific tissue or organ and instead
manifests itself generally throughout the body. Since the mechanism is not well known
for ME/CFS, treatments that directly target the disease do not currently exist. Also, a
diagnostic device that could potentially better identify ME/CFS patients is needed since
one does currently not exist. Over one million Americans currently suffer from ME/CFS
with varying degrees of severity and with a better diagnostic test would clarify how
widespread the disease is. [2] Since the disease affects the body generally without
targeting a specific organ, we decided to study how ME/CFS affects red blood cells
(RBCs) which make up around 40% of the total blood volume and are responsible for
transporting oxygen to tissue and counteracting diseases respectively.
1.2 RBC Deformation and Possible Ways to Measure Deformability
Since capillaries can be as small as 3-4 µm and blood cells are typically 6-8 µm,
RBCs must deform to travel through the vessel and fulfill their function. [3] RBC
deformability in this case describes the ability for the cell to change its shape when
confined, like when it travels in a capillary. It has been shown that loss of RBC
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deformability can be directly tied to several different diseases including sickle cell
anemia and malaria. [4,5] Blood cell deformability has also been observed to decrease
while kept in storage after being drawn from the body, a process during which RBCs
slowly lose their function. [6] Therefore, the deformability of the RBCs can be tied to
both the health of the patient and the viability of the cell. It has also been shown that
RBCs in patients with ME/CFS exhibit signs of oxidative damage. [7,8] Since blood cell
deformability has been shown as an important biomarker for patient health and cell
function, it was determined that the deformability of RBCs in both patients with ME/CFS
and healthy patients should be studied. [9,10,11]
To measure cell deformability, a method is required that provides accurate data, has a
relatively simple set-up and offers a high throughput of cells to analyze. There are several
different techniques, each with its own strengths and weaknesses. The first possible
method is atomic force microscopy (AFM) which uses a probe attached to a flexible
cantilever to deform the surface of the cell. [12] The magnitude of this deformation can
be used to measure the Young’s modulus, a number describing the stress/strain
relationship for a material. However, this method is highly sensitive to experimental
conditions, meaning multiple measurements must be taken to properly evaluate the level
of deformation which lowers the throughput.
Another method is micropipette aspiration in which a single cell is drawn into a glass
tube which has a diameter smaller than the diameter of the cell. [13] The movement of
the cell can be tracked and is used to predict deformation. However, the results from this
process can be unreliable since even small errors in the experimental set-up such as
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changes in negative pressure due to mechanical vibrations can affect the accuracy of the
results. Also, the set-up generally takes several minutes for each measurement meaning
this process is very low throughput.
A third method is optical tweezers which use a two-beam laser trap to optically
induce deformation on single suspended cells and the resulting deformation
measurements are used to characterize the deformability of the cell. [14] Unfortunately,
this method has a complex setup and cells may undergo thermal damage if exposed to the
laser trap for prolonged periods of time. All three of these methods are traditional
approaches used to measure cell deformability, but they all suffer from low throughput
and complex setups which can lead to inaccuracies in results.
1.3 Microfluidic Techniques to Measure Cell Deformability
A final possibility is a microfluidic device which involves flowing cells through
microscale channels smaller than the cell itself and then observing how cells deform. [15]
Unlike the previous three experimental methods, this method offers high throughput of
200-300 cells analyzed per hour, a relatively simple experimental set-up and only
requires a small amount of blood. This leads to more accurate measurements and more
practical applications. The microscale vessels in the device have the added benefit of
mimicking blood vessels, meaning the deformations that the RBCs undergo are similar to
what they would undergo in the body.
Typically, to properly generate a microfluidic device, a mold is fabricated using a
process known as photolithography which can potentially pattern microscale features on
a substrate, typically silicon. [16,17] Light is used to transfer a geometric pattern from a
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photomask to a photoresist on a substrate which either degrades or strengthens the
uncovered photo-sensitive material depending on whether the process is positive or
negative photoresist. A solvent called a developer is then applied to the surface which
either dissolves the regions exposed or not exposed to the light. Photolithography is a
useful technique because it can produce extremely small patterns, potentially nanometers
in size, and reproduces the desired pattern very accurately. However, this process can be
very costly depending on the size of the features desired and requires extremely clean
operating conditions since any debris can cause defects to the pattern. A process known
as soft lithography then produces the actual microfluidic device. [16, 17] A polymer
known as polydimethylsiloxane (PDMS) is mixed with a cross-linking agent and poured
on top of the mold generated from the photolithography process. The mold is then cured
in an oven and then after a few hours, the PDMS is peeled off, leaving the embossed
features on the bottom. This device along with a glass slide are then plasma bonded and
sealed together to form the final device. Plasma bonding involves using a machine known
as a plasma cleaner to treat the surfaces of the glass and PDMS with plasma and allows
the PDMS and glass to stick to one another. The process of photolithography and soft
lithography is shown in Figure 1 (a, b).
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Figure 1: Fabrication of a Microfluidic Device with Photolithography and Soft
Lithography (reprinted with permission from Taylor and Francis) [16]
The final step in this technique involves flowing cells into the device and analyzing
them. After generating the final microfluidic device in Figure 1, cells are injected at an
inlet and a pressure gradient is generated to flow the cells through a microconstriction,
which causes the cells to deform. As the cells flow through the channel, an inverted
microscope with a high-speed camera are then used to capture the resulting images.
Imaging software can be used to analyze the video. [17] The way the cells deform and
how they are analyzed is determined by the design of the device.
1.4 Significance of Using Microfluidics to Measure RBC Deformability in ME/CFS
Patients
There are many important implications of using this device to measure blood cell
deformability in ME/CFS patients. It will enable us to study the potential mechanism of
the disease and thus provide more direct treatment possibilities for sufferers of ME/CFS
and possibly a cure afterwards as well. There are also potential clinical applications.
Since the microfluidic device offers a high throughput and involves a relatively simple
experimental set-up, RBCs could easily be taken from potential ME/CFS patients and
analyzed using the device for the diagnosis of ME/CFS
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CHAPTER TWO: LITERATURE REVIEW
2.1 Ways to Measure Cell Deformability Using a Microfluidic Device
First, the design of the microfluidic device must be determined that can reliably
measure RBC deformability. There are a few requirements that a design must have to
generate reliable data in a reasonable amount of time. First, the design must be high
throughput, meaning it can analyze many cells in a short amount of time. Second, it must
allow for single cell analysis so each cell can be assessed individually. Third, the design
must allow the experimental conditions, like pressure gradient, to be constant across the
device. As mentioned in Sections 1.2 and 1.3 above, the device must involve a
microconstriction smaller than the RBC size of 6 µm to force the cell to deform. The
most recent available research on this topic used many different designs to evaluate cell
deformability.
A rudimentary design is shown in Figure 2, wherein posts that were spaced 5 µm
from each other to simulate a 5 µm Nucleopore filter. To test the device, suspensions of
RBCs were created at 1% hematocrit in phosphate buffer saline (PBS) with increasing
concentrations of glutaraldehyde from 0.01% - 0.6%. [18] Glutaraldehyde is a crosslinker reagent that reacts with the RBCs and stiffens them. The resulting suspensions
were then flown through the filter analog at a pressure of 20 cmH2O. Deformability was
measured by filtration time or how long the buffer took to flow through the filter. From
these experiments, it was found that RBCs treated with up to 0.06% glutaraldehyde
flowed freely through the device. From 0.06% to 0.09%, the cells began to lose their
deformability and could not pass through the filter. At higher concentrations, however,

6

the cells lost their deformability to the point that they could not pack the gaps as
effectively, and therefore the buffer is more able to flow through the filter resulting in
lower filtration times. While this device design offers high throughput, it does not allow
for single cell analysis and doesn’t measure for cell deformability past a certain point.

Figure 2: RBC Filterability vs. Glutaraldehyde Concentration (reprinted with permission
from Royal Society of Chemistry) [18]
A similar device that improves upon the filter design previously is shown in Figure 3,
which shows a device that consists of a series of constrictions that gradually decrease in
size from 5 µm to 1.5 µm. [19] A single cell enters the series of constrictions and
deforms through the channel until the cell is plugged. The distance the cell traveled is
measured to analyze the cell’s deformability. The researchers compared the device to gel
electrophoresis which separates strands of DNA. The design also incorporates several
channels in parallel with one another so that many cells can be evaluated with one device.
The device also allows for single cell analysis unlike the previous design. However, as

7

cells are plugged in the channels, the pressure gradient of the device changes as the flow
is impeded. Therefore, the experimental conditions are not kept constant throughout the
device.

Figure 3: Microfluidic Cell-Phoresis Device Design (reprinted with permission from
Royal Society of Chemistry) [19]
Another device that allows for single cell analysis is shown in Figure 4, wherein a
device is able to analyze a single HeLa cell flowing through a microconstriction like the
previous design. [17] However, in this device, the cell didn’t get plugged in the channel
since the channels were only slightly smaller than the HeLa cells which are 10-16 µm.
There are many advantages of this design in comparison to the previous two. It allows for
high throughput and single cell analysis, but it also keeps the pressure gradient constant
since the cells don’t get plugged.
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Figure 4: Device Design with Multiple Microconstrictions for Single Cell
Analysis (reprinted with permission from Royal Society of Chemistry) [17]
The researchers also set out to model the cell deforming in the channel. By applying
the lubrication approximation, the no-slip boundary condition, volume conservation and
assuming the cell was a cylindrical pellet, the researchers solved the Navier-Stokes
equation for incompressible flow in an angular axisymmetric region as Equation 1 as a
function of pressure gradient k, medium viscosity μm, channel size a, cell size rc and cell
velocity Uc. To evaluate the Young’s modulus of the cell, the shear stress acting on the
cell wall was solved using a combination of the Navier-Stokes equation used in Equation
1 and Equation 2. Further, tension force acting on the cell is defined in Equation 3 where
A is surface area of cell and l is length of deformed cell. Assuming the cell was a
viscoelastic solid material and using the Kelvin-Voight viscoelastic solid model, the
tension force T could be related to shear modulus G in Equation 4 where λ is the
extension ratio of the cell, which is the ratio of the deformed length of the cell to the
undeformed diameter of the cell, t is the time ηm is the membrane surface viscosity and ε
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is void fraction of the channel. Shear modulus is then related to Young’s modulus Ec, the
value that measures a material’s stress to strain ratio, of the cell by calculating the amount
of shear stress resulting from fluid flow around the cell, in Equation 5 where ν is
Poisson’s ratio. The Young’s modulus could then be solved by using Equation 6 which is
found by equating the Navier-Stokes derived expression from Equations 1 and 2 and the
Kelvin-Voight derived expression in Equation 4 and 5. Equation 1 and 6 provide a
theoretical model that directly relates Young’s modulus, which directly measures the
deformability of the cell, to measurable cell properties like velocity and size.

Equation 1: Momentum Balance to Solve for Cell Radius [17]

Equation 2: Definition of Shear Stress Acting on Surface of Cell Wall [17]
Equation 3: Relation of Shear Stress to Tension Forces Acting on Cell [17]

Equation 4: Definition of Tension Force Acting on Cell [17]
Equation 5: Relation of Shear Modulus to Young’s Modulus [17]

Equation 6: Prediction of Young’s Modulus of Cell [17]
Finally, another improvement upon the previous design is to incorporate geometric
alignment. As seen in Figure 5, the researchers Tsai added an alignment channel to the
conventional design for microfluidic devices measuring RBC deformability. [20] In a
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conventional design, the RBCs enter the evaluation channel at different alignments since
they are all entering the channel at different angles. If the cells don’t enter the channel in
similar alignments, they might not deform through the channel in a consistent manner.
Therefore, to solve this problem, the researchers added a small alignment channel before
the chamber leading into the evaluation channel. This allows the cells to enter the device
at similar alignments, causing less noise in the data and allows the cells to return to their
original shape before entering the evaluation channel. Incorporating this feature into the
final design will generate more reliable data

Figure 5: Comparison of Design with Geometric Alignment to Conventional
Design (reprinted with permission from Royal Society of Chemistry) [20]
2.2 RBC Deformation as Biomarker for Function
When RBCs flow through the body, they must deform to transport oxygen through
capillaries where most of the oxygen transfer between blood and tissue takes place.
Therefore, RBCs must be at a certain level of deformability so that the body can function.
As a result, many researchers have theorized that RBC deformability can be used as a
biomarker for disease and metabolic disorders, especially if they don’t attack a specific
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organ or tissue. Researchers have also found that loss of RBC deformability can also be
tied to cell death resulting from the RBC storage lesion.
One disease that researchers found RBC deformability to be a biomarker for is sickle
cell anemia. Sickle cell anemia causes the body to produce misshapen RBCs in the shape
of sickle rather than the normal biconcave discoid shape. This causes RBCs to burst in
flow which results in anemia as the body has trouble replacing the blood cells lost. RBCs
also stick to vessel walls and can bunch together to impede the flow of blood. Since the
disease directly affects the shape of the cell, the deformability of the RBCs was estimated
under flow conditions using a microfluidic device. [4]
For their experiment, a microfluidic device with a functionalized fibronectin surface
was used. Fibronectin is a glycoprotein present on blood vessel wall surface that binds to
integrin α4β1 receptor on the RBC and causes it to attach to the vessel wall. Thus, RBCs
were able to attach to the wall of the microfluidic device. Shear stress was applied by
increasing flow in increments until the cells detached. From the start of the experiment
until the cells detached, the aspect ratio of the cell was measured. According to Figure 6,
it was found that the healthy cell dramatically changed its aspect ratio in response to
stress. Meanwhile, the sickle cell RBCs were divided into two subsets, one with cells
exhibiting a biconcave shape and one with cells that lacked a biconcave shape. It was
determined that that both these subsets of cells had their aspect ratios remain constant
throughout the experiment. It was concluded that sickle RBCs barely changed shape and
were therefore less deformable under flow while healthy RBCs dramatically changed
shape and were therefore more deformable under flow.
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Figure 6: Dynamic deformability analysis of single sickle and healthy RBCs (reprinted
with permission from World Scientific) [4]
Loss of RBC deformability has also been found to be a biomarker for malaria.
Malaria is a parasitic disease that infects RBCs. The device shown in Figure 7 was used
to separate infected RBCs from healthy RBCs using the phenomenon known as the
margination effect. [5] The margination effect is the process by which stiffer, larger cells
in flow migrate to the sides of the walls while smaller, more deformable cells migrate
towards the center of the vessel. The device above has two outlets, one on the sides for
infected RBCs and one in the middle for healthy RBCs. The blood is then analyzed to see
what percentage of RBCs in the patient are healthy. It was observed that the device could
recover 75% of early stage infected RBCs and 90% of late stage infected RBCs. While
this device has many potential clinical applications, it does not allow for single cell
analysis meaning it won’t be useful for my purposes.
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Figure 7: Microfluidic Device for Margination of Malaria Infected RBCs (reprinted with
permission from Royal Society of Chemistry) [5]
RBC deformability can also be used as a biomarker for metabolic disorders such as
obesity. A microfluidic device that flowed RBCs into a constriction and they measured
how the major axis of the cell increased as a function of how long it traveled into the
constriction. [21] The elongation index was then measured, which is the ratio of the
length of the cell after it enters the constriction to before it enters the constriction. As
seen in Figure 8, it was found that RBCs from participants that were obese with
metabolic abnormalities (OMA+) had an elongation index significantly lower than
healthy RBCs (OMA-) at every point along the constriction. The histograms in Fig. 7b
also shows the distribution of elongation indexes for OMA+ RBCs is significantly lower
than the OMA- RBC elongation indexes. It was concluded that since OMA+ RBCs
elongated less in the constriction, that they were less deformable than the OMA- RBCs.
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Figure 8: Elongation Index for OMA+ RBCs (Blue) vs OMA- RBCs (Gray) (reprinted
with permission from Public Library of Science) [21]
Finally, RBC deformability has also been found to be a biomarker for the RBC
storage lesion. As RBCs for use in blood transfusions age in cold storage, energy sources
in the cell begin to decrease. This results in reduced structural integrity in the cell
membrane. Therefore, the RBCs become more fragile and the circulatory lifespan of the
RBC drops from 120 days to potentially hours or minutes. The longer the cells are kept in
storage, the more the storage lesion becomes a problem. A microfluidic device was used
to assess the deformability of the RBC and thus the degree to which the cells are affected
by the storage lesion. [6] The experiment used a device that forced the RBCs into a 1.5
µm constriction and steadily increased the pressure until the cell squeezes through.
According to Figure 9, it was determined that on average the longer the RBCs were
placed in cold storage, the pressure required increases. It was also found that the
distribution of pressure required became broader so that some RBCs squeezed through at
a lower pressure similar to healthy RBCs and some squeezed through at much higher
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pressures. Potentially this device could be used to assess the degree to which RBCs are
affected by the storage lesion and therefore whether they should be used in transfusion.

Figure 9: Effect of RBC Storage Lesion on RBC Deformation (reprinted with permission
from Elsevier) [6]
2.3 Effects of ME/CFS on RBCs
While very little is known about how ME/CFS affects RBC deformability, the effects
of ME/CFS on the cardiovascular system are better understood. It has been found that
ME/CFS is correlated with increases in blood pressure and heart rate, oxidative damage
to RBCs, alterations to RBC membrane composition and loss of white blood cell
function. This research establishes a baseline for the hypothesis that ME/CFS affects
RBC deformability.
It has been found that ME/CFS does affect the cardiovascular system. One
experiment measured the heart rate and blood pressure of adolescent patients with
ME/CFS while they were asleep and while they were awake. [22] Their results were
shown in Table 1. They found that there was no statistical difference between the control
and ME/CFS groups for blood pressure taken during while awake, but that there was a
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statistical difference in diastolic blood pressure (DBP) taken during sleep. They also
found that there was a statistical difference in heart rate measurements taken both while
asleep and while awake. They concluded that these results indicated “altered automatic
cardiovascular regulation in ME/CFS” which potentially indicates that ME/CFS does
affect blood cells.
Table 1: Twenty‐four‐hours ambulatory recordings of systolic blood pressure (SBP)
which is the maximum pressure during one heartbeat, diastolic blood pressure (DBP)
which is the minimum pressure between heart beats, mean arterial pressure (MAP) and
heart rate (HR). Mean (SD) [22]
ME/CFS Patients
Controls
p(n=44)
(n=52)
value*
SBP Awake (mmHg)
120 (10.2)
122 (8.2)
.082
SBP Asleep (mmHg)

110.8 (10.0)

107.3 (8.9)

.130

SBP Total (mmHg)

118.2 (9.9)

118.3 (8.3)

.651

DBP Awake (mmHg)

69.2 (7.5)

70.1 (4.0)

.329

DBP Asleep (mmHg)

57.9 (5.8)

53.7 (4.2)

<.001

DBP Total (mmHg)

66.8 (7.0)

65.4 (4.0)

.651

MAP Awake (mmHg)

86.0 (8.0)

87.7 (4.9)

.124

MAP Asleep (mmHg)

75.5 (6.6)

71.6 (5.3)

.007

MAP Total (mmHg)

84.0 (7.6)

83.1 (5.0)

.732

HR Awake (beats/min)

80 (10)

76 (8)

.026

HR Asleep (beats/min)

68 (9)

63 (9)

.004

HR Total (beats/min)

77 (9)

72 (8)

.004
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Since it was established that ME/CFS does affect the cardiovascular system, there
have been investigations into how ME/CFS affects the blood cells themselves.
Specifically, research has been focused on oxidative damage ME/CFS RBCs. Oxidative
damage is caused by the imbalance of reactive oxygen species (ROS) which include free
radicals and peroxides and antioxidants. If there aren’t enough antioxidants to maintain
the normal redox state of the cell, ROS can cause damage to components of the cell.
Richards and others investigated signs of oxidative damage in both ME/CFS and healthy
patients by measuring the levels of 2,3-diphosphoglycerate (2,3-DPG), glutathione
(GSH), malondialdehyde (MDA) and methemoglobinemia (MetHb). [23] According to
Table 2, the difference in levels of 2,3-DPG, MDA and MetHb were statistically
significant. 2,3-DPG is a phosphate produced in RBCs which lowers Hb’s affinity for O2
and thereby facilitating O2 released to tissue. The researchers speculate that this could
result from a decrease in deformability which would reduce oxygen delivery to tissue
which might be compensated by an increase in 2,3-DPG. Levels of MDA, which is a
product of lipid peroxidation, were significantly greater in ME/CFS patients which
indicates that ROS are causing damage to the membrane lipids. Higher levels of MetHb,
which is a product of Hb degradation, were also found in ME/CFS patients indicating that
there was oxidative damage to the Hb molecules. The researchers ultimately concluded
that there were significant signs of oxidative damage to ME/CFS RBCs and that could
potentially affect deformability.
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Table 2: RBC Antioxidants and Oxidation Products of ME/CFS Sufferers and Control
[23]
2,3-DPG
GSH
MDA (nmol/ml)
MetHb (%)
(µmol/ml)
(mg/100ml)
Controls
4.97±0.99
73.1±8.26
27.18±14.29
0.55±.71
(n=41)
ME/CFS
5.82±0.98
74.33±10.44
39.98±26.64
1.26±1.46
(n=33)
One way that researchers have attempted to see how ME/CFS affects RBCs is by
investigating how ME/CFS affects the level of essential fatty acids in RBC membranes.
Liu and others isolated RBC membranes from both ME/CFS and healthy patients. [24]
They then used gas chromatography to test the membranes for presence of different
essential fatty acids. According to their results in Table 3, they found that levels of
arachidonic (C20:4) and docasahexanoic (C22:6) acids were significantly decreased in
ME/CFS patients while levels of non-essential oleic (C18:1) and palmitic (C16:0) acids
were significantly increased in ME/CFS patients. The researchers theorized that the lower
levels of arachidonic and docasahexanoic acids could be due to increased oxidative stress
in ME/CFS patients. Oxidative stress could lead to excessive oxidation and therefore
reduction levels of the fatty acids. Lack of these essential fatty acids would be
detrimental to ME/CFS patients since the human body cannot synthesize them on their
own. Although, the effects of ME/CFS on RBC structure is not discussed, the data shows
that ME/CFS affects RBC membranes.
Table 3: RBC Membrane Fatty Acid Analysis for Healthy and ME/CFS Patients [23]
C16:0
C18:0
C18:1
C18:2
C20:3
C20:4
C22:6
Control
(n=37)
ME/CFS
(n=42)

.2597

.2136

.1307

.1394

.0231

.1718

.0612

.2736

.2195

.1364

.1401

.0226

.1552

.0562
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P-value

.026

.083

.013

.842

.659

.009

.034

*Values expressed as % of total determined fatty acids
Finally, the rheological properties of ME/CFS RBCs have also been investigated.
Brenu and others investigated the deformability of RBCs using an ektacytometer which
measures how the sample deforms at different shear stresses. [7] The experimenters
compared the elongation indexes for both healthy and ME/CFS patients’ blood at
different shear stresses from 0.5-20 Pa. The results are shown in Figure 10. While the
researchers originally hypothesized that deformability would be different between
ME/CFS and healthy blood samples, their results did not show a statistical difference
between the two subsets. However, there are some problems using this approach to
measure deformability. The ektacytometer is less sensitive than a microfluidic device
since it does not analyze the cells individually and only analyzes the population.
Therefore, there is still room for the study of RBC deformability in ME/CFS patients.

Figure 10: Assessment of RBC Deformability in ME/CFS using an ektacyometer
(reprinted with permission from Biomed Central) [7]
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CHAPTER THREE: RESEARCH OBJECTIVE
3.1 Objective
The objective of this project is to test the hypothesis that blood cell deformability is
altered in ME/CFS patients. This hypothesis will be testing by evaluating deformability
of both RBCs and lymphocytes from ME/CFS and healthy patients using a microfluidic
channel. There are three main goals for the overall objective. Goal 1 involves designing a
microfluidic device and then developing an automation technique to evaluate
deformability automatically. Goal 2 involves evaluating the deformability of RBCs from
ME/CFS and healthy control patients and measuring the differences. Finally, goal 3
involves employing suitable statistical methods and identifying deformability metrics to
distinguish RBC deformability in ME/CFS patients from healthy subjects.
3.2 Justification
Current microfluidic techniques for analyzing the deformability of cells have many
advantages over other techniques including a higher throughput, a relatively simple setup
and allowance of single cell analysis. Therefore, using a microfluidic technique allows
for many cells to be analyzed individually so that confidence in the results can be
sufficiently high. Furthermore, loss of deformability in RBCs has been found to be a
biomarker for other diseases and disorders, meaning there is precedent to study how CFS
affects RBC deformability. Finally, ME/CFS has been found to affect the cardiovascular
system and cause oxidative damage to RBCs. Consequently, an investigation into the loss
of deformability of RBCs in ME/CFS patients is needed not only because the current
literature indicates there could be a loss, but also because it will allow the disease to be
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better understood. This could lead to potential diagnostic devices and treatments that
directly target the disease mechanism.
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CHAPTER FOUR: MATERIALS AND METHODS
The microfluidic technique to measure RBC deformability involves three different
steps. The first step is to fabricate the microfluidic device by creating a silicon wafer
mold and then using PDMS to generate the final device. The second step is to run the
experiment by flowing RBCs through the device. The final step is to record high speed
videos of RBCs flowing through the device and using imaging software to analyze the
deformation. The details of these steps, including materials, that were used are given
below.
4.1 Materials
Materials for the project are divided into the microfluidic device fabrication step and
the experimental step. The microfluidic device fabrication step is divided further into the
silicon wafer fabrication step and the soft lithography step.
For the silicon wafer fabrication step, after designing the device using Solidworks, a
chrome-on-glass photomask based on that design was obtained from a company (Photo
Sciences Inc.). The photomask was used to transfer the design to a silicon wafer using
photolithography and a negative photoresist SU-8 2000 (MicroChem Catalog#
NC0349842). For the soft lithography step, polydimethylsiloxane (PDMS; Dow Corning
Catalog# NC9285739) was used to replicate the mold and create the polymeric device
with embedded microchannels. This device was then bonded to clean glass slides (Fisher
Scientific, Catalog# 12-550-A3) using a plasma cleaner (Harrick Plasma, Catalog#
NC9332171).
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For the experimental step, to prepare the RBCs for flow, the RBCs were suspended in
1x phosphate buffer saline (PBS, Gibco Catalog# 70-011-044). To prepare the channels
for flow, they were first cleaned and wetted with 1x PBS and .1x Pluronic F-127
(MilliporeSigma, 54-002-550ML).
4.2 Methods
To fabricate the device, PDMS was mixed with its curing agent in a 10:1 ratio in a 50
ml centrifuge tube by using a vortex mixer for 30 seconds and then inverting the tube for
15 seconds. This was repeated 10 times. Next, the mixed PDMS was poured over the
silicon wafer mold which was allowed to cure at 90°C for 3 hours. The cured PDMS chip
was cut out of the mold and sealed to a glass slide using plasma bonding. This final
device was put in the oven at 90°C for 1 hour to strengthen the plasma bonding.
RBC samples were obtained from confirmed ME/CFS patients diagnosed using the
Canadian Consensus Criteria and from age/gender paired healthy controls (HC). Samples
were provided by the Stanford Genome Technology Center who also obtained written
consent. The first step of sample preparation was to isolate the RBCs via centrifugation.
Whole blood from both healthy control and ME/CFS patients were spun at 1200 g for 10
minutes. After centrifugation, the plasma and buffy coat layer were extracted and
discarded leaving the bottom RBC layer. For the final step, the RBCs were suspended to
a final concentration of ~107 cells/ml in 1x PBS.
The RBC suspension was fed through a microfluidic device which utilizes the design
shown in Figure 11. The design involves channels that gradually decrease in size
successively until the 5 µm x 5 µm test channel. It incorporates eight different test
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channels for higher throughput and has two bypass channels that are 50 µm wide each to
alleviate resistance to flow and therefore increase throughput as well.

Figure 11: Microfluidic Device Design
The RBC suspension was fed into the device by generating a vacuum of -2 psi. While
the RBCs deformed through test channel, they were observed using a microscope at 40x
objective and recorded at 4000 fps using a high-speed camera (Phantom VEO 410L). The
video files were then saved so they could be analyzed. For each condition, ME/CFS and
HC, two microfluidic devices were used to make sure that there was a backup in case
there is a blockage in the channel that goes unnoticed during the experiment and to check
if data is reliable for all devices.
4.3 Image Analysis
For the experiments conducted using the Leica microscope, videos were able to be
processed in a way that the cells could be tracked automatically. The RBCs were studied
moving through the 5 µm x 5 µm test channel as seen in Figure 12 using the high-speed
videos taken during the experimental step. Video clips from the microscope were
imported to ImagePro as Multipage TIFF (tagged image file format) files. This format
allows video files to be contained as multiple pages (frames) with lossless compression.
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Figure 12: Progression of single RBC Deforming in 5 µm Channel
The motion detect tool was then used to highlight objects that change their positions
between frames. When this was applied, a new image was created with lower intensity
pixels displaying the non-moving objects. This means that static regions and objects, such
as the background, were darkened uniformly. The result was an image showing only the
moving cells. The walls of the microfluidic channels and vignetting from the camera
were effectively removed. A low-pass filter was applied to smooth the image and reduce
noise. Homogenous regions of similar pixel intensity (i.e. biological cells) were
emphasized. This aided the motion tracking step by making the target cells more
prominent in the image and therefore more easily identified by the software. To further
enhance the image, the black level and white level were adjusted slightly to increase
contrast between the cells and the background. At this stage, the image was fully
prepared for motion tracking. A rectangular region of interest was placed around the
microfluidic channels so only cells flowing through the region were tracked. A filter for
the major axis of the objects is set between 7 and 15 µm. This ensures that only objects
within the diameter range of typical RBCs were tracked. The threshold for tracking
objects was set from 0 to 123.
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4.4 Statistical Analysis
For the experiments conducted on the Amscope microscope, the cells were not
tracked automatically and had to be analyzed manually. The five different parameters
measured were average transit velocity, entry time, undeformed length, deformed length
and elongation index. Average transit velocity was calculated by measuring the amount
of time for each cell to travel 100 µm in the test channel. Entry time was calculated by
measuring the time between the cell coming into contact with the test channel to when it
fully entered the channel. Undeformed length and deformed length were measured as the
major axis of the cell outside of and inside of the test channel respectively. Elongation
index was then calculated as the ratio of the two.
For the experiments conducted on the Leica microscope which is shown in Figure 13,
the cells could be tracked automatically as described in Section 4.3 using ImagePro.
Many different parameters can be tracked using ImagePro as the cell moves through the
channel including the velocity, major axis, elongation index and entry time and exit time
of the cell. For the major axis, ImagePro approximates each cell as an ellipse and
measures the maximum diameter of that ellipse. Elongation Index is the ratio of the major
axis of the cell after it enters the channel to the major axis of the cell before it enters the
channel. Entry time describes how long it takes for the cell to enter the channel. One of
the advantages of tracking the cells automatically is that the major axis of the cell could
be measured at specific points outside and inside of the test channel. This means that for
this step, the cell’s undeformed length was measured at a constant distance from the test
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channel entrance and the cell’s deformed length was measured at a constant distance into
the test channel.

(a)

(b)

(c)

Figure 13: Leica Experimental Setup (a) Overview of entire setup including
microscope/camera on right, pressure gauge and pump in center and computer on right
(b) Closeup of pressure gauge attached to the pump (c) Closeup of microfluidic device
with pressure gauge apparatus attached
After collecting the above measurements for both ME/CFS and healthy control
samples, statistical analysis was done using a one-way analysis of variance (ANOVA) ttest with Tukey’s post hoc test to determine whether the differences between the
conditions are statistically significant. The statistical analysis was conducted using
MATLAB.
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4.5 Safety
There were a few hazards to take note of when working with polydimethylsiloxane
(PDMS). It could cause irritation if it comes into contact with eyes. If PDMS was spilled,
it must be wiped up by an inert material and put in a normal disposal container. Proper
PPE such as safety glasses, chemical resistant gloves and proper clothing like long
sleeves and closed-toed shoes should be worn. The container must be closed and be kept
at temperatures lower than 150°C or else formaldehyde, which is classified as a known
carcinogen by the National Toxicology Program, might form. PDMS is not for injection
into humans.
Working with phosphate buffered saline (PBS) or F-127 also has certain risks. PBS
consists of 97% water, 1% sodium chloride, 1% potassium chloride and 1% sodium
phosphate by weight. It may cause skin, eye or respiratory tract infections. Therefore,
eyewashers and safety showers should be accessible in the lab. Proper PPE such as splash
goggles, latex gloves, lab coat and a vapor respirator should be used when handling PBS.
Proper clothing such as closed-toed shoes should also be worn.
Preparation of the blood samples carried a significant risk for transmitting diseases.
To ensure the experimenter does not come into contact with the blood samples, the
samples were prepared in a fume hood while wearing proper PPE such as lab coats and
latex gloves along with proper clothing such as long pants and long-sleeved shirts along
with closed-toed shoes. Eyewashers and safety showers should also be accessible.
A list of all chemicals used along with relevant safety hazard information is shown in
Table 4. The MSDS for each chemical is reviewed before each experiment. The
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experimenter should also take note of the location of the safety shower and eyewash in
the event of a spill. Other lab personnel should also be present nearby in case of
emergency.

Chemical Health
PDMS
0
PBS

1

F-127

1

Table 4. Chemical List
Flammability
Reactivity
PPE
1
0
Goggles, Gloves,
Long Sleeves
0
0
Splash Goggles,
Gloves, Lab Coat,
Vapor Respirator
0
0
Goggles, Lab
Coats, Gloves
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Other

CHAPTER FIVE: RESULTS AND DISCUSSION
5.1 Determination of Average Flow Velocity Profiles in Channels
Before the experiments with patients’ blood, the microfluidic test channels needed to
be characterized and to confirm a constansy of flow at -2 psi. To do this, 2 µm beads in
1x PBS were fed at 2 psi through the 5µm test channel and the average transit velocity
was recorded for each bead. Since, unlike RBCs, the beads could flow through the
channel without resistance, they could accurately characterize the velocity of flow in the
channel. While transit velocity could vary by the amount of beads in the channel at the
same time, it was assumed that the variance was negligible since they could flow through
the channel without significantly impeding or plugging flow.
Three experimental trials were then conducted to make sure that the flow would be
consistent between trials. This meant that not only did the average velocity between the
trials needed to be consistent, but the distribution needed to be consistent as well. For
many of the graphs below, the data was displayed using violin plots which show both the
mean of each data set and the distribution of the data. The distribution was depicted with
wider sections where more of the data was located and thinner sections where less of the
data was located. As shown in Figure 14, the means and distributions of average transit
velocity between the three trials are roughly equivalent and did not statistically differ
between one another (8485  247 m/s vs. 8790  291 m/s vs. 9609  252 m/s,
p>0.05). With the confirmation that the microfluidic device had a test channel with a
relatively constant flow, it can be concluded that the RBCs were going through the device
with a consistent flow profile.
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Figure 14: Distribution of Average Transit Velocity for Bead Trials based on the time
taken by 2µm beads to travel 100μm distance inside the test channels for one experiment
involving three different trials on three different days
5.2 Characterization of the Ability of Microconstrictions to Evaluate RBC Deformability
After it was validated that the flow through the test channel was constant, the test
channel’s ability to measure changes in RBC deformability also needed to be assessed.
To do this, RBCs from healthy subjects were collected and then treated with 0.01%
glutaraldehyde in 1x PBS for 10 minutes. Glutaraldehyde has been shown to significantly
decrease RBC deformability by crosslinking RBC proteins especially those in the
specterin network. [24] Both untreated and glutaraldehyde treated RBCs were then fed
through the device at 2 psi and their deformation was observed.
The results are presented as average +/- SEM (standard error of mean) for three
different experiments. As seen in Figure 15, it was observed that glutaraldehyde treated
cells had significantly lower velocity (8056  1140 m/s vs. 5371  1200 m/s; n=3;
p<0.05), a lower elongation index (1.067  0.026 vs. 1.033  0.04; n=3; p<0.05) that
isn’t statistically significant and a significantly higher entry time (1.61  0.45 ms vs.
2.33  0.65 ms; n=3; p<0.05). There are also some other interesting observations.
According to Figure 15, the spread of data for both entry time and elongation index is
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wider for glutaraldehyde treated RBCs than for untreated RBCs meaning that the
glutaraldehyde affects some RBCs more than others resulting in a wider spread for all
three deformability attributes. The standard error of mean (SEM) for all three attributes is
higher for glutaraldehyde treated blood. With this data, it can be concluded that the test
channels in the microfluidic device can reliably detect reductions in RBC deformability.

*
(a)

*
(b)

(c)
Figure 15: Glutaraldehyde Trials, Figure is representative of one experiment performed
on three different days with blood drawn from three different donors. The symbols denote
statistical significance (P<0.05, two-tailed ANOVA). (a) Distribution of Average Transit
Velocity based on the time taken by RBCs to travel 100μm distance inside the test
channels for Untreated and Glutaraldehyde Treated RBCs (b) Distribution of Entry Time
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based on the time between the RBCs coming into contact with the test channel entrance
to when the cell is fully entered for Untreated and Glutaraldehyde Treated RBCs (c)
Distribution of Elongation Index defined as the ratio of the length of RBCs in the test
channel to the length before entry into the test channel for Untreated and Glutaraldehyde
Treated RBCs
5.3 Determination of RBC Deformability Differences in CFS Patients Using Manual
Image Analysis
Since it has now been determined that flow at -2 psi through the test channels is
constant and that the test channels are sensitive enough to detect differences in RBC
deformability, the experiments with healthy control (HC) and ME/CFS blood could then
be reliably conducted. Each ME/CFS patient was paired with a healthy control that was
age and gender matched. For the first 16 patient pairs that were tested, the videos were
analyzed manually to measure RBC deformability and the results of each experiment is
shown in Figures 16-21.
The results are presented as an average +/- SEM of 16 patients for both HC and
ME/CFS. According to Figure 16, the transit velocity of the cells through the channel was
significantly greater for healthy RBCs than ME/CFS RBCs (9123  431 m/s vs. 8026 
350 m/s; n = 16; p< 0.05). The distributions for entry time seen in Figure 17 also show
that the average entry time for healthy RBCs is significantly decreased compared to
ME/CFS RBCs (1.93  0.085 ms vs. 2.27  0.124 ms; n = 16; p< 0.05).
Before the cell even enters the test channel, according to Figure 18, the length of the
cells was significantly greater for ME/CFS RBCs (10.47 ± 0.294 m vs. 11.02 ± 0.274
m; n=16; p<0.05). The 10% increase in undeformed RBC length in ME/CFS patients
does potentially indicate that it would not deform as easily through the test channel since
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they must strain themselves more to squeeze through the test channel. After the cells
enter the channel, healthy RBCs were found to have a significantly increased length than
ME/CFS RBCs (11.41 ± 0.46 m vs. 11.07 ± 0.35 m; n=16; p<0.05) according to Figure
19. These results were especially significant because the trend for deformed RBC length
is reversed from undeformed RBC length where healthy RBCs had decreased length.
Interestingly, it would have been expected that ME/CFS RBCs would have longer
deformed lengths since their undeformed lengths are greater, but the results show that this
is not the case. These results indicate the ease with which healthy RBCs can modulate
their shape after entering the test channel and the difficulty ME/CFS RBCs must
modulate their shape.
Therefore, measuring the ratio of the deformed length of each RBC to their
undeformed length would be a useful measurement since it would approximate how
much the cell modulates its shape as it enters the test channel. This measurement, called
the Elongation Index, was calculated from the undeformed and deformed lengths and is
shown in Figure 20. Elongation Index was found to be significantly less for ME/CFS
RBCs then for healthy RBCs (1.09  0.014 vs. 1.01  0.032; n = 16; p< 0.05). The box
and dot plots showing the averages of each patient for each deformability parameter is
shown in Figure 21. These results confirm what was suggested by the deformed RBC
length data and proves that healthy RBCs more readily change their shape in the test
channel than ME/CFS RBCs. Also, of note is the distribution of deformed cell lengths
and elongation index. As seen in Figures 19 and 20, the spread of deformed length and
elongation index was wider for ME/CFS RBCs than for healthy RBCs. This could
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potentially indicate that the disease affects some RBCs more than others meaning that the
ME/CFS RBC suspension could have cells that are both infected and uninfected.
Since it has already been concluded that ME/CFS RBCs don’t change shape as easily
according to the cell length and Elongation Index data, the decrease in average transit
velocity and increase in entry time likely stems from ME/CFS RBCs taking longer to
change shape. Like with the deformed length and Elongation Index data, the distribution
of the entry time shown in Figure 17(b) seems to be more spread out for ME/CFS patients
vs. healthy patients. However, that doesn’t seem to be the case with average transit
velocity with the spread between healthy and ME/CFS RBCs being somewhat
comparable. This could be because entry time has more to do with shape change since it
is during this time that the cell must change their shape to fit the test channel. However,
since it has already been established that the flow through the channel is constant, the
average transit velocity data might not see the same distribution as the data that is more
associated with shape like elongation index and entry time.
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(a)

(b)

(c)

(d)
Figure 16: Distribution of Average Transit Velocity for 16 Separate ME/CFS and Healthy
Patient Pairs with Manual Image Analysis. Figure is representative of one experiment
performed on 16 different days (a) Patients 1-4 (b) Patients 5-8 (c) Patient 9-12 (d)
Patient 13-16 based on the time taken by RBCs to travel 100μm distance inside the test
channels
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(a)

(b)

(c)

(d)
Figure 17: Distribution of Entry Time for 16 Separate ME/CFS and Healthy Patient Pairs with
Manual Image Analysis. Figure is representative of one experiment performed on 16 different
days (a) Patients 1-4 (b) Patients 5-8 (c) Patients 9-12 (d) Patients 13-16 based on the time
between the RBCs coming into contact with the test channel entrance to when the cell is fully
entered
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(a)

(b)

(c)

(d)
Figure 18: Distribution of Undeformed Length for 16 Separate ME/CFS and Healthy
Patient Pairs with Manual Image Analysis. Figure is representative of one experiment
performed on 16 different days. (a) Patients 1-4 (b) Patients 5-8 (c) Patients 9-12 (d)
Patients 13-16 based on the major axis of the cell calculated before the cell enters the test
channel
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(a)

(b)

(c)

(d)
Figure 19: Distribution of Deformed Length for 16 Separate ME/CFS and Healthy Patient
Pairs with Manual Image Analysis. Figure is representative of one experiment performed
on 16 different days. (a) Patients 1-4 (b) Patients 5-8 (c) Patients 9-12 (d) Patients 13-16
based on the ratio of the major axis of the cell calculated after the cell fully enters the test
channel
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(a)

(b)

(c)

(d)
Figure 20: Distribution of Elongation Index for 16 Separate ME/CFS and Healthy Patient
Pairs with Manual Image Analysis. Figure is representative of one experiment performed
on 16 different days. (a) Patients 1-4 (b) Patients 5-8 (c) Patients 9-12 (d) Patients 13-16
based on the ratio of the length of RBCs in the test channel to the length before entry into
the test channel
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*
*
(a)

(b)

*

*
(c)

(d)

*
(e)
Figure 21: Combined Dot and Box Plots Showing Distribution of RBC Deformability
Parameters for 16 Separate ME/CFS and Healthy Patient Pairs with Manual Image
Analysis. Figure is representative of one experiment performed on 16 different days. Dots
represent average for each patient sample. The symbols denote statistical significance
(P<0.05, two-tailed ANOVA). (a) Transit Velocity (b) Entry Time (c) Elongation Index
(d) Undeformed Length (e) Deformed Length
5.4 Determination of RBC Deformability Differences in CFS Patients Using Automated
Image Analysis
After completing the 16 patient pair trials disclosed in the previous section, the
research team was able to gain access to a new Leica microscope with a higher quality
objective lens. The improved objective effectively doubled the resolution of the recorded
videos. This meant that it was now easier to automate the image analysis as mentioned in
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Chapter 4.3 above. Six different patient pairs were analyzed using the automated cell
analysis and the results are displayed in Figures 22-27.
The results are presented as an average +/- SEM of six patients for HC and CFS. As
seen in Figure 22, the transit velocity of the cells through the channel was significantly
greater for healthy RBCs than ME/CFS RBCs (8912  552 m/s vs. 8163  510 m/s; n
= 6; p< 0.05) which was a trend similar to what was found with the manual image
analysis. The distributions for entry time seen in Figure 23 also showed that the average
entry time for healthy RBCs was significantly decreased compared to ME/CFS RBCs
(1.27  0.223 ms vs. 1.38  0.268; n =6; p< 0.05).
As with the trials conducted with the manual image analysis, according to Figure 24,
the RBC length before the cell enters the channel was greater for healthy RBCs (11.45
± .268 m vs. 11.33 ± 0.410 m; n=6; p>0.05). This is in contrast to the trials conducted
with the manual image analysis which found healthy RBCs were smaller before they
entered the channel. After the cell enters the channel, the length of the RBC was found to
be higher for healthy control RBCs than for ME/CFS RBCs as seen in Figure 25 which is
similar to the trend seen with the manual image analysis trials (11.92 ± 0.357 m vs.
11.75 ± 0.406 m; n=6; p>0.05). Finally, looking at Figure 26, the elongation index data
was found to also have a similar trend to the manual image analysis trials with ME/CFS
RBCs having a smaller elongation index than healthy RBCs (1.046 ± 0.0261 vs. 1.045
± .0264; n=6; p>0.05). The box and dot plots showing the averages of each patient for
each deformability parameter is shown in Figure 27. However, these differences in cell
length values aren’t statistically significant like the results from the manual image
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analysis. Another difference seen between the manual image analysis trial data and the
automated analysis experimental data was the significant increase in average cell length
measurements for both deformed and undeformed length. These differences could be due
to the increase in resolution from the microscope. Since the resolution is greater, the edge
of the cell was more easily discernible meaning that it’s easier to assess the cell length
from one side to the other because the cell is easier to see in total. There also needs to be
a larger sample size to better assess how the automated image analysis setup affects cell
length measurements
Unlike with the manual image analysis trials, the distribution spread for entry time
and the data associated with length do not exhibit differences with ME/CFS RBCs having
data that was more spread out than healthy control. The trend seen with the undeformed
length also flipped and the difference in elongation index wasn’t statistically significant
like for the manual image analysis. This could be due to there being less trials overall for
the automated image analysis meaning the results overall are less comprehensive. Also,
especially for the cell length data, since the measurements can be more precise, changes
in RBC length might be less pronounced and therefore there will be less of a distribution
overall in RBC length data.

44

(a)

(b)
Figure 22: Distribution of Average Transit Velocity for 6 Separate ME/CFS and Healthy
Patient Sample Pairs on Automated Image Analysis. Figure is representative of one
experiment performed on 6 different days. (a) Patients 1-3 (b) Patients 4-6 based on the
time taken by RBCs to travel 100μm distance inside the test channels

(a)

(b)
Figure 23: Distribution of Entry Time for 6 Separate ME/CFS and Healthy Patient
Sample Pairs on Automated Image Analysis. Figure is representative of one experiment
performed on 6 different days. (a) Patients 1-3 (b) Patients 4-6 based on the time
between the RBCs coming into contact with the test channel entrance to when the cell is
fully entered
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(a)

(b)
Figure 24: Distribution of Undeformed Length for 6 Separate ME/CFS and Healthy
Patient Sample Pairs on Automated Image Analysis. Figure is representative of one
experiment performed on 6 different days. (a) Patients 1-3 (b) Patients 4-6 based on the
major axis of the cell calculated before the cell enters the test channel

(a)

(b)
Figure 25: Distribution of Deformed Length for 6 Separate ME/CFS and Healthy Patient
Sample Pairs on Automated Image Analysis. Figure is representative of one experiment
performed on 6 different days. (a) Patients 1-3 (b) Patients 4-6 based on the major axis of
the cell calculated after the cell fully enters the test channel
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(a)

(b)
Figure 26: Distribution of Elongation Index for 6 Separate ME/CFS and Healthy Patient
Sample Pairs on Automated Image Analysis. Figure is representative of one experiment
performed on 6 different days. (a) Patients 1-3 (b) Patients 4-6 based on the ratio of the
length of RBCs in the test channel to the length before entry into the test channel
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*
*
(a)

(b)

(c)

(d)

(e)
Figure 27: Combined Dot and Box Plots Showing Distribution of RBC Deformability
Parameters for 6 Separate ME/CFS and Healthy Patient Pairs with Automated Image
Analysis. Figure is representative of one experiment performed on 6 different days. Dots
represent average for each patient sample. The symbols denote statistical significance
(P<0.05, two-tailed ANOVA). (a) Transit Velocity (b) Entry Time (c) Elongation Index
(d) Undeformed Length (e) Deformed Length
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CHAPTER SIX: CONCLUSION AND FUTURE WORK
In conclusion, the results show that RBCs from ME/CFS patients are moderately less
deformable than RBCs from healthy control patients. The lower deformability of
ME/CFS RBCs could potentially explain many of the symptoms of ME/CFS since it
could lead to defects in microvascular perfusion and tissue oxygenation. Taken together,
the results show the promising signs of establishing a biomarker for ME/CFS and
providing the basis for a diagnostic test. However, there must more work to be done
before that happens. First, many more patient pairs must be tested to ensure that the
conclusion is a biomarker. Second, we must find ways to increase the differences in
deformability between ME/CFS and healthy RBCs whether by finding different
parameters to measure deformability by or by designing a new microfluidic device.
Currently, we are working on a new microfluidic device that could potentially increase
the differences. We are also measuring different parameters such as cell area and
circularity. Thirdly, we also need to establish properties of ME/CFS RBCs themselves
without comparing to a healthy control so that a quick diagnostic test can be established.
Finally, the effect of using whole blood instead of pure RBCs must be studied to make a
potential diagnostic test simpler and require less blood since whole blood separation
wouldn’t be required.
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